Companion Diagnostics Market Analysis, Share and Future Scope

Companion diagnostics offers a set of tools that facilitates biological and clinical information to the pharmaceutical companies that they have to overcome. Companion diagnostics help physicians to improve the treatment decisions for the patients depending on their response to current treatments. Companion diagnostics approach to medication is transforming the healthcare industry by eliminating unfavorable reactions, improving treatment outcomes, and reducing the cost and time difficulties associated with conventional methods of medication.



Companion diagnostic is basically a bio-analytical method designed to evaluate whether the patient will respond favorably to the specific medical treatment or not. The market is fully dependent on discovery of biomarkers, and research and development of new drugs. With the surge in research and development of targeted rehabilitations and innovation of new biomarkers for a range of conditions, the global companion diagnostics market is growing at healthy rate.

Several targeted drugs in association with a companion diagnostics test are developed and have reached to large numbers of consumers. Large and small biopharmaceutical companies actively develop drug diagnostic combination products which are fast to surpass traditional drugs, favoring the concept of one-size-fits-all. U.S. Food and Drug Administration (FDA) have approved companion diagnostics for lung colorectal, breast, and melanoma. Some of the companion diagnostics devices are erbitux vectibix, lynparza, gilotrif, herceptin, exjade, gleevec, zelboraf and tarceva.

Browse full report at: https://www.psmarketresearch.com/market-analysis/companion-diagnostics-market

North America had the largest companion diagnostics market because of the increasing incidence of cancer and increased healthcare awareness. Whereas, Asia-Pacific is the fastest growing market of companion diagnostics owing to the strengthening healthcare services and increasing medical tourism in developing countries such as India and China.

Some of the major competitors in companion diagnostics market are Biogenex Laboratories Inc, Agilent Technologies, Inc., Abbott Laboratories, Inc., Beckman Coulter, Inc., Danaher Corporation, Myriad Genetics, Inc., Qiagen N.V., bioMérieux SA, F. Hoffmann-La Roche AG, and General Electric Company.

DNA Sequencing Market Analysis and Forecast Report 2024

The global DNA Sequencing market size is projected to achieve a lucrative growth based on the advent of technological innovations and extensive clinical applications. The market is expected to be led by consumable products, in terms of both size and growth during the forecast period (2018-2023). This is attributed to the extensive use of consumables for sample preparation, cluster generation, and other processes during the course of experiments.

DNA sequencing make use of various technological platforms for fragmentation and sequencing studies. These technological platforms include sequencing by synthesis, ion semiconductor sequencing, sequencing by ligation, pyrosequencing, single-molecule-real-time sequencing, chain termination sequencing, and nanopore sequencing. Sequencing by synthesis is the most widely used platform in sequencing protocols and is the largest contributor to the DNA sequencing market, on the basis of product type. The category is also anticipated to witness fastest growth in demand, during the forecast period.

The key trends observed in the DNA sequencing industry are surge in clinical assessment through personalized genomics, increase in oncological research, demand for easy and fast clinical diagnosis, and adoption of high throughput technology.

The growing collaborations and partnerships among key players is expected to increase their market share in the coming years. For instance, in April 2017, Genome Diagnostics B.V. (GenDx) signed a global reseller agreement with Thermo Fisher Scientific, Inc. next-generation sequencing instruments. Under the agreement, GenDx and its distributors will have the rights to offer an end to end workflow to Human Leukocyte Antigen (HLA) typing laboratories that includes the Ion Torrent brand of next-generation sequencing (NGS) systems and consumables with GenDx assays and analysis software for allelic level HLA typing analyses.

Some of the other key players in the global market include Illumina, Inc, Pacific Biosciences of California, Inc., Siemens AG, ZS Genetics, Inc, Abbott Laboratories, Li-Cor, Inc., F. Hoffmann-La Roche Ltd., Oxford Nanopore Technologies, and Agilent Technologies, Inc.

Cell-Based Assays Market and its Growth Landscape for the Next Few Years

Cell-based assays are commonly used analytical tools to measure the cell proliferation, viability, cytotoxicity, production and screening of compounds. Owing to the rise in cases of chronic disorders and increasing inclination of the government organizations and private firms funding in the health sector, there has been a consistent high demand of new therapeutic drug discovery. In this regard, the cell-based assays have advantage over the conventional animal based models for drug discovery. Cell-based assays utilizes live cell models to investigate the cellular mechanism when exposed to external stimuli and provide precise information about the intracellular molecular targets required in drug discovery screening. In contrary to the animal based methods, the resultant toxicity and safety measures in cell based assays are monitored at an early stage of an experiment, hence it reduces the additional cost that can be generated due to high failure rates if monitored at a later stage of an experiment. In combination to high-throughput screening techniques, cell- based assays have gained its interest in the area of research and development for primary as well as secondary screening. However, cell-based assay’s experimental instruments and kits are expensive and require high skilled professionals to conduct the procedures as the cost of experimental procedure is relatively high. This acts as one of the key restraining factors governing the cell-based assays markets.

Request for report sample at: https://www.psmarketresearch.com/market-analysis/cell-based-assays-market/report-sample

The global cell-based assays market is anticipated to grow on account of rise in the incidence of chronic diseases, increasing public and private intervention in the area of research and development, inclination towards cell-based assays over traditional biochemical assays, and a sustained increase in the drug discovery activity. According to the Centers for Disease Control and Prevention, 7 out of ten causes of death were due to chronic ailments, in 2014. Additionally, the cell-based assay techniques have many advantages over conventional methodology. The continuous advancement in technological products under cell-based assay along with their cost effectiveness are the major drivers of the growth of global cell-based assays market.

Certain factors such as, the involvement of developing countries in the Asia-Pacific region such as China and India, advancement in technology such as emergence of 3D cell-based assays, increase in demand of toxicological testing of screened compounds in drug discovery along with the varied application of cell-based assays present a vast opportunity for the manufacturers in the global cell-based assays market.

Browse full report at: https://www.psmarketresearch.com/market-analysis/cell-based-assays-market

Some of the major players operating in the global cell-based assays market include Merck KGaA, Becton, Dickinson and Company, Promega Corporation, Danaher Corporation, GE Healthcare, Thermo Fisher Scientific Inc., Cell Signaling Technology, Inc., BioTek Instruments Inc., Lonza Group, ProQinase GmbH, Charles River Laboratories Inc, Cisbio Bioassays, Miltenyi Biotec, Cell Biolabs, Inc., DiscoverX Corporation, BioAgilytix Labs., Enzo Life Sciences, Inc., Aurelia Bioscience Ltd., Selexis SA, and QGel SA.

Source: P&S Intelligence

Cardiovascular Information System Market Analysis and Forecast Report 2024

The global cardiovascular information system market is witnessing significant growth due to increasing prevalence of cardiovascular diseases, growing government initiates towards electronic health record system implementation and growing rate of medication errors. The remote access to data and images, and reduced IT burden in the diagnostic center and hospitals are supporting the demand of CVIS. Moreover, better interoperability and increasing healthcare cost are further expected to boost the market.

Get report sample at: https://www.psmarketresearch.com/market-analysis/cardiovascular-information-system-market/report-sample

Based on mode of operation, web-based segment leads the global market in terms of size, owing to high rate of awareness, improved interoperability, reduced IT burden in hospitals and relatively less cost. Based on component, the market for service segment is expected to grow at the fastest rate during the forecast period, due to upgradation of services for the complex software introduction and requirement for extensive training.

Cardiovascular disease is the disease of heart and blood vessels, which includes conditions such as hypertension, coronary heart disease, heart failure, cerebrovascular disease and rheumatic heart disease. It is the leading cause of premature death around the world. According to the WHO, globally about 17.5 million people died due to cardiovascular diseases in 2012, while the number is expected to reach 23.3 million by 2030.

Globally, the cardiovascular information system market is expected to witness the fastest growth in Asia-Pacific during the forecast period. The highest growth in the region is attributed to large pool of patient, improving healthcare infrastructure, increasing incidence of cardiovascular disease, and growing medical tourism in the region.

The key players operating in the global cardiovascular information system market are Philips Healthcare, McKesson Corporation, General Electric Company, Siemens AG, AGFA Healthcare and Cerner Corporation.

Source: P&S Intelligence

Top Key Players Operating In the Healthcare EDI Market and Growth Strategies

Healthcare electronic data interchange (EDI) facilitates the exchange of healthcare data which is processed using computer software in a standardized format. Healthcare industry processes a large number of documents such as medical records of patients, healthcare claims, and reimbursement records. Healthcare EDI helps in the exchange of this information among healthcare institutions, healthcare professionals, and patients. The use of healthcare EDI increases accuracy, improves productivity, helps in faster identification of errors, consumes less time, secures exchange of information and leads to ease of work for the healthcare providers, healthcare payers, and pharmacies. Healthcare EDI finds application in insurance and reimbursement data management, clinical trials and regulatory data management, and medical and dental patient database management. They key players such as Dell Technologies Inc. are prompting the growth of the global healthcare EDI market. In February 2017, Dell Technologies Inc. quickened the digital transformation in healthcare EDI market with the introduction of cloud integration solution for healthcare EDI.

Get report sample at: https://www.psmarketresearch.com/market-analysis/healthcare-edi-market/report-sample

Global healthcare EDI market is expected to grow significantly during the forecast period. Some of the major factors driving growth of the market include expanding base of patient due to the increasing prevalence of chronic diseases, rising need to curtail healthcare costs, and government support for healthcare EDI. According to the World Health Organization (WHO), chronic disease is the leading cause of mortality globally, comprising 60% of all deaths. Also, approximately 17.7 million people died from cardiovascular diseases in 2015, representing 31% of all global deaths. Of these deaths, an approximate of 7.4 million deaths were due to coronary heart disease and 6.7 million were due to stroke. WHO also reported that globally 8.8 million people died from cancer which is 1 in 6 of all global deaths in 2015. With the rise in these chronic diseases, the volume of patient is also increasing. Moreover, these large number of deaths also prompts the end users to avail healthcare EDI products for different reimbursements claims.

The key trend witnessed in the global healthcare EDI market is increasing number of research and development activities. With the rising prevalence of adoption of advanced technology in the healthcare market, the key players are investing more on the research and development on healthcare EDI, for the growth of the global healthcare EDI market. Additionally, increasing use of EDI in healthcare manufacturing and distribution industry and growing focus on integration platform as a service (IPAAS) are major trends observed in the global healthcare EDI market. The increase in outsourcing of EDI services and introduction of ICD-11 guidelines are creating ample opportunities for the growth of the global healthcare EDI market.

Browse full report at: https://www.psmarketresearch.com/market-analysis/healthcare-edi-market

Some of the key players in the global healthcare EDI market are GE Healthcare, Cognizant Technology Corporation, Cerner Corporation, Axway Software SA, Dell Technologies Inc., Synnex Corporation, McKesson Corporation, Allscripts Healthcare Solutions Inc., SSI Group, LLC, Comarch SA, Optum Inc., and Quality Systems Inc.

Source: P&S Intelligence